ACURX PHARMACEUTICALS INC (ACXP)
US00510M1045 - Common Stock
Stay updated with the stocks that are on the move in today's after-hours session.
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...
Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...
Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)
Acurx has now received positive written responses from the EMA (European Medicines Agency) under its Scientific Advice Procedure that the clinical,...
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications
Following the previously announced successful End of Phase 2 Meeting achieving agreement with FDA on non-clinical and clinical Phase 3-readiness, Acurx has now...
Acurx-Vorstand genehmigt die Verwendung von Bitcoin als Währungsreserve
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) („wir", „Acurx" oder „Unternehmen"), ein biopharmazeutisches Unternehmen mit Spezialisierung auf die...
Le conseil d'administration d'Acurx approuve le Bitcoin en tant qu'actif de réserve de trésorerie
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ : ACXP) (« nous », « Acurx » ou la « société »), une société biopharmaceutique en phase avancée de...
La junta directiva de Acurx aprueba Bitcoin como activo de reserva de tesorería
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("nosotros" o "Acurx" o la "compañía"), una compañía biofarmacéutica en etapa avanzada que...
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...
Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update
Acurx is proud to sponsor this inaugural Scientific Symposium of the Peggy Lillis Foundation (PLF) for C. Diff Education & Advocacy An update of ibezapolstat...
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...
Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference
The data presented indicate a favorable gut bile acid profile which may contribute to ibezapostat's beneficial anti-recurrence effect in patients with C....
Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of...
Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late- stage biopharmaceutical company developing a new class of...
Bloomberg’s “New to The Street” Segment by PetVivo Inc. (OTCQB: PETV) Stocks to Watch This Week inside….
New to the Street Announces Exclusive Bloomberg Lineup for Saturday October 12 at 6:30 PM EST
New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST
ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP), today announced it will be featured as a presenting company at the H.C. Wainwright 26th Annual...
ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q2 2024
ACXP stock results show that Acurx Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acurx Pharmaceuticals (NASDAQ:ACXP) just reported results for the second quarte...
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small...
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference
Additional analyses of clinical and microbiological data from the Phase 2b segment show favorable gut microbiome changes including increased relative...
ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q1 2024
ACXP stock results show that Acurx Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new...
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...